Hemodynamic changes following wingspan stent placement--a quantitative magnetic resonance angiography study

BACKGROUND

Quantitative magnetic resonance angiography (QMRA) is a noninvasive imaging modality that provides anatomic and physiologic measurements of arteries. We used QMRA to assess hemodynamic changes following Wingspan stent placement for intracranial stenosis.

METHODS

We reviewed patients treated with Wingspan stents for intracranial stenosis who had baseline and follow-up QMRA data. We compared volumetric flow rates (VFRs) (mL/minute) pre- and poststenting using paired t-tests. P<.05 was considered significant.

RESULTS

Among 9 patients (mean age 65.8 years, mean 71% degree of stenosis), lesions were located in the supraclinoid internal carotid arteries in 3, middle cerebral arteries in 3, and intracranial vertebrobasilar arteries in 3. VFR and degree of stenosis were moderately correlated (r=-.670, P=.002). The mean VFR in the stenotic artery increased from 81.2 mL/minute to 133.3 mL/minute (P=.020) or by 64.2% after stenting. Total cerebral blood flow, flow in nonstented vessels, and collateral flow in circle of Willis vessels did not significantly change.

CONCLUSION

We found that QMRA is a promising noninvasive method for the measurement of cerebral hemodynamics following intracranial Wingspan stent placement. Larger prospective studies are needed to confirm our findings.

The Utility of Quantitative Magnetic Resonance Angiography in the Assessment of Intracranial In-Stent Stenosis

Background and Purpose— Noninvasive screening for intracranial in-stent stenosis is often limited by artifact because of the stent or associated coils. We aimed to determine the utility of quantitative MRA (QMRA) as a screening tool for detecting intracranial in-stent stenosis.

Methods— We reviewed 14 patients who had intracranial stent placement with follow-up QMRA and conventional angiography at our institution. Socio-demographic, medical, clinical, and imaging data were abstracted from medical charts. A blinded interventional neurologist reviewed all angiograms for presence of >50% in-stent stenosis. We tested QMRA (mL/min) at varying thresholds as a predictor of angiographic results.

Results— Among 14 patients (mean age, 62 years; 12 female, 2 male), 13 patients had Neuroform stents placed for wide-neck cerebral aneurysms and 1 patient had a Wingspan stent placement for atherosclerotic stenosis. Lesions were located in the intracranial internal carotid artery in 57.2% (n=8), the middle cerebral artery in 14.3% (n=2), and vertebrobasilar arteries in 28.6% (n=4). On follow-up angiography, 2 patients (14.3%) had >50% in-stent stenosis on angiography. Time-of-flight MRA was nondiagnostic in each case because of artifact from the stent or coils. A >20% reduction in vessel-specific blood flow by QMRA was associated with presence of >50% in-stent stenosis on angiography ( P =0.033). As a screening tool to predict >50% angiographic in-stent stenosis, the sensitivity, specificity, positive predictive value, and negative predictive value of QMRA were 100%, 92%, 67%, and 100%, respectively.

Conclusion— We found that QMRA is a promising screening tool to detect intracranial in-stent stenosis. Future prospective studies should focus on whether QMRA has a role in the detection of radiographic restenosis and prediction of clinical events.

Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting

BACKGROUND AND PURPOSE

The prevalence of antiplatelet drug resistance among patients who undergo cerebrovascular stent placement is unknown. We aimed to assess the feasibility of monitoring antiplatelet drug effects in a single-center cohort undergoing cerebrovascular stent placement.

MATERIALS AND METHODS

We prospectively collected medical, laboratory, and radiographic data on patients who underwent cerebrovascular stent placement. We used the rapid platelet function assay-aspirin (RPFA-ASA) to calculate aspirin reaction units (ARU) and the P2Y12 assay to calculate P2Y12 reaction units and percentage platelet inhibition. Aspirin resistance was defined as ARU > 550, whereas clopidogrel resistance was defined as percentage platelet inhibition < 40%.

RESULTS

Among 76 patients, stent indications were the following: wide-neck aneurysm (57, 75.0%), symptomatic intracranial stenosis (12, 15.7%), carotid stenosis (5, 6.6%), and vertebral stenosis (2, 2.6%). For aspirin, the median dosage per week was 1300 mg and median ARU was 410. Among 71 patients on aspirin, 3 patients (4.2%) were resistant; there was a significant inverse correlation between aspirin dose and ARU (r = -0.31, P = .01). Among 55 patients on clopidogrel, the median dosage per week was 525 mg with a mean platelet inhibition of 43.2%. Twenty-eight patients (51.9%) were clopidogrel-resistant. In a multivariable linear regression model, age older than 55 years (b = -16.3, P = .020) and diabetes (b = -26.8, P = .015) were inversely related to percentage platelet inhibition.

CONCLUSIONS

Using point-of-care tests, we found that aspirin resistance is relatively uncommon, whereas clopidogrel resistance occurred in half of patients undergoing cerebrovascular stent placement. Further studies should focus on ideal doses, timing, and duration of antiplatelet therapy for cerebrovascular stent placement.